Bottom line
GTHRX vs XLV: the short answer
GTHRX (INVESCO Health Care Fund) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both mutual funds.
XLV is cheaper at 0.08% vs 1.32% — a difference of $124 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +3.5% for GTHRX.
Updated Nov 19, 2026
GTHRX vs XLV side by side
| GTHRX | XLV | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Invesco | SPDR (State Street) |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.32% | 0.08% |
| Annual cost per $10k | $132 | $8 |
| 10-yr cost on $10k (prospectus) | $1,590 | $103 |
| Max front load | 0% | None |
| 12b-1 fee | 0.5% | 0.02% |
| 1-yr return | +15.2% | +14.5% |
| 5-yr return (annualized) | +3.5% | +8.1% |
| 10-yr return (annualized) | +6.1% | +9.8% |
| Best quarter | +19.6% | +14.5% |
| Worst quarter | −16.5% | −12.7% |
| Net assets (fund) | $1.2B | $40.6B |
| Number of holdings | 82 | 65 |
| Portfolio turnover | 59% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GTHRX | XLV | Difference |
|---|---|---|---|
| 2024 | +4.0% | +2.5% | +1.5% |
| 2023 | +3.1% | +2.0% | +1.1% |
| 2022 | −13.5% | −2.1% | −11.5% |
| 2021 | +12.2% | +25.9% | −13.7% |
| 2020 | +14.5% | +13.3% | +1.2% |
| 2019 | +32.0% | +20.7% | +11.3% |
| 2018 | +0.5% | +6.3% | −5.8% |
| 2017 | +15.5% | +21.7% | −6.2% |
| 2016 | −11.7% | −2.8% | −8.9% |
Source: Fund prospectus bar charts
Holdings overlap
10 of GTHRX's top 25 holdings also appear in XLV's top 25.
| Holding | GTHRX | XLV |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 16.51% |
| Johnson & Johnson | 6.76% | 10.64% |
| UnitedHealth Group Inc. | 6.17% | 6.57% |
| Merck & Co., Inc. | 4.59% | 5.52% |
| AbbVie Inc. | 4.03% | 7.74% |
| Gilead Sciences, Inc. | 3.63% | 2.73% |
| CVS Health Corp. | 2.52% | 2.30% |
| Cardinal Health, Inc. | 2.10% | 0.97% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.19% |
| Thermo Fisher Scientific Inc. | 1.55% | 3.24% |
Source: SEC Form N-PORT
GTHRX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FAQ
What is the difference between GTHRX and XLV?
Which is cheaper, GTHRX or XLV?
Should I own both GTHRX and XLV?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.